Compare Devon Energy Corp (DVN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs ResMed Inc. — how do they compare? Devon Energy Corp trades at $45.11 (market cap $49.94B), while ResMed Inc. trades at $223.49 (market cap $32.61B). The key difference: Devon Energy Corp is the larger of the two by market cap, and Devon Energy Corp pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| DVN | RMD | |
|---|---|---|
Market Cap | $49.94B | $32.61B |
Sector | Energy | Health |
52-Week High | $52.07 | $293.73 |
52-Week Low | $31.74 | $182.82 |
Enterprise Value | $60.68B | $31.97B |
Dividend Yield | 2.82% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $45.36, up 5.54% with strong technical momentum and bullish analyst sentiment. The company delivered robust Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising dividends 33% and accelerating debt reduction. Valuation remains attractive with P/E of 9.87 and EV/EBITDA of 6.89, supported by $1.7B Q2 free cash flow and $8B buyback authorization.
Outlook remains positive with merger synergies tracking ahead of schedule and 2026 revenue guidance of $19.7B. Key risks include oil price volatility and integration execution from the Coterra merger. With 71% analyst buy ratings and $61.91 consensus target representing 36% upside, DVN offers compelling value for energy investors seeking growth and shareholder returns.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
